

RESPONSE UNDER 37 C.F.R. § 1.116
EXPEDITED PROCEDURE REQUESTED
EXAMINING GROUP 1600
PATENT
Attorney Docket No. 07680.0018-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Seng H. CHENG et al.)	
)	
Application No.: 10/758,773)	Group Art Unit: 1632
)	
Filed: January 16, 2004)	Examiner: Shin-Lin CHEN
)	
For: COMBINATION GENE THERAPY AND)	Confirmation No.: 6298
ENZYME REPLACEMENT THERAPY FOR)	
TREATMENT OF LYSOSOMAL STORAGE)	Mail Stop AF
DISEASES (As Amended))	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

AMENDMENT AFTER FINAL

In reply to the Final Office Action mailed February 12, 2008, the period for response having been extended to August 12, 2008 by a request for extension of time and fee payment filed concurrently herewith, and pursuant to 37 C.F.R. § 1.116, Applicants propose that this application be amended as follows:

Amendments to the Claims begin on page 2 of this paper.

Remarks/Arguments begin on page 6 of this paper.

Attachments to this amendment include:

- Ziegler et al., *Human Gene Therapy* 19:609-621 (June 2008) (*Ziegler 2008*)
- Cerezyme® Prescribing Information
- Myozyme® Prescribing Information

- Aldurazyme® Prescribing Information
- Elaprase® Prescribing Information
- Naglazyme® Prescribing Information
- <http://www.fda.gov/cder/regulatory/applications/laws.htm>
- <http://www.emea.europa.eu/humandocs/PDFs/EPAR/Cerezyme/070697en1.pdf>